Medicines And Healthcare Products Regulatory Agency

Type: Organization
Name: Medicines And Healthcare Products Regulatory Agency
First reported Apr 18 2014 - Updated Apr 18 2014 - 1 reports

ABPI Lauds MHRA’s 2014-2015 Business Plan

The UK’s Medicines and Healthcare products Regulatory Agency’s 2014-2015 business plan, released this week, supports safe innovation, UK growth, safety and vigilance, says Association of the British Pharmaceutical Industry CEO Stephen Whitehead.Steps ... [Published FDA News - Apr 18 2014]
First reported Apr 16 2014 - Updated Apr 16 2014 - 3 reports

UK industryMHRA generics quality forum launches

The British Generics Manufacturers Association (BGMA) and the Medicines and Healthcare products Regulatory Agency (MHRA) have established a new forum with the aim of ensuring the manufacturing ... ... [Published Big News Network - Apr 16 2014]
First reported Apr 16 2014 - Updated Apr 16 2014 - 2 reports

MHRA business plan new products services income streams

The Medicines and Healthcare products Regulatory Agency (MHRA) has published its business plan for 2014/15, which sets out how the Agency intends to develop in response to the changing business ... ... [Published Big News Network - Apr 16 2014]
First reported Apr 16 2014 - Updated Apr 16 2014 - 1 reports

Pharmacist appointed director of licensing at MHRA

A trained pharmacist has been appointed director of licensing at the Medicines and Healthcare products Regulatory Agency.Dr Siu Ping Lam, who holds a PhD in pharmaceutical chemistry, officially took up the post yesterday (April 15) having been acting ... [Published Pharmacy.Biz - Apr 16 2014]
First reported Apr 16 2014 - Updated Apr 16 2014 - 1 reports

MHRA appoints new Director of Licensing

The Medicines and Healthcare products Regulatory Agency (MHRA) has appointed Dr Siu Ping Lam as its new Director of Licensing.Read more ›Lilly and T1D Exchange have entered into a five-year collaboration in a bid to improve care for Type-1 diabetes p ... [Published Pharma Field - Apr 16 2014]
First reported Apr 14 2014 - Updated Apr 14 2014 - 1 reports

MOLECULAR PROFILES EXPANDS TECHNOLOGY WITH GMP HOT MELT EXTRUSION

Nottingham, UK - ., a subsidiary of Columbia Laboratories, Inc., (Nasdaq: CBRX) has completed a significant investment into additional equipment as part of a wider project focusing on enabling technologies that facilitate processing of difficult-to-progress ... [Published PharmiWeb - Apr 14 2014]
First reported Apr 13 2014 - Updated Apr 13 2014 - 1 reports

3M’s Tegaderm CHG IV dressing is first transparent dressing ind...

“Global technology company 3M announced today its Tegaderm CHG ( chlorhexidine gluconate) I.V. securement dressing is the first transparent antimicrobial dressing to be clinically proven and indicated to reduce catheter -related bloodstream infections ... [Published IVTEAM - Apr 13 2014]
First reported Apr 08 2014 - Updated Apr 08 2014 - 2 reports

MHRA: many healthcare apps likely to qualify as medical devices

The Medicines and Healthcare products Regulatory Agency (MHRA) has answered a long-held question facing people in the rapidly growing world of healthcare apps: are apps subject to a regulatory regime? The MHRA has confirmed that in many instances software ... [Published Matthew Arnold & Baldwin LLP - Apr 08 2014]
First reported Apr 06 2014 - Updated Apr 06 2014 - 1 reports

3M’s Tegaderm CHG IV dressing is first...

#IVTEAM # Intravenous products: “Global technology company 3M announced today its Tegaderm CHG ( chlorhexidine gluconate) I.V. securement dressing is the first transparent antimicrobial dressing to be clinically proven and indicated to reduce catheter ... [Published IVTEAM - Apr 06 2014]
First reported Apr 02 2014 - Updated Apr 03 2014 - 2 reports

Kopran gets Certificate of Compliance from UKMHRA

Kopran has informed that the United Kingdom, Medicines and Healthcare products Regulatory Agency (UKMHRA) has granted the Certificate of Compliance with principles and guidelines of Good Manufacturing Practice for the Finished Dosage Forms facility located ... [Published India Everyday - Apr 02 2014]
First reported Mar 27 2014 - Updated Mar 28 2014 - 2 reports

e-Therapeutics announces recruitment resumes into UK Phase I ETS2101 cancer trial

e-Therapeutics has announced that it has received approval from Medicines and Healthcare products Regulatory Agency (MHRA) to recommence recruitment of new patients into its ETS2101 Phase Ia solid ... ... [Published Big News Network - Mar 28 2014]
First reported Mar 24 2014 - Updated Mar 24 2014 - 1 reports

New reporting methods for medicines errors

New national networks to maximise learning and minimise harm relating to medication and device errors are to be set up by the autumn, NHS England and the Medicines and Healthcare products Regulatory Agency have announced.The organisations sent out two ... [Published Pharmacy Magazine - Mar 24 2014]

Quotes

"As an industry, we rank quality issues extremely highly and are therefore pleased to be proactively engaging on the topics and challenges which impact them" said Thomas Broeer, chair of the BGMA (pictured)
...British American Tobacco is even seeking a licence for one of its alternative nicotine delivery devices, and has met the regulator "to discuss the potential budgetary implications of using this type of product" . So smoking cessation services may soon be in the deeply conflicted position of prescribing tobacco industry products, and the tobacco industry's lo...
...The Institute of Cancer Research (ICR) and Honorary Consultant in Medical Oncology at The Royal Marsden, and an investigator for the trial, said, "Advanced prostate cancer remains a difficult disease to treat due to the development of various resistance mechanisms. We are very interested in developing new personalized therapies to improve treatment outcomes for these patients. Through Arno Therapeutics' early trial in advanced castration-resistant prostate cancer, we hope to gain a deeper understanding of the safety profile and potential anti-cancer activity of onapristone with the goal of accelerating the development of the APR biomarker and this targeted anti-progestin."
Alex Zukiwski , MD, Chief Medical Officer of Arno Therapeutics , commented, "Tolerance to chemotherapy and various targeted therapies is known to be different in males undergoing androgen deprivation treatment. While the percentage of castration-resistant prostate cancer that is APR positive remains to be determined, the initial series of preclinical tumor specimens we examined has demonstrated evidence of APR, and we are looking forward to evaluating the safety and anti-cancer activity of onapristone in this patient population."

More Content

All (109) | News (103) | Reports (0) | Blogs (5) | Audio/Video (0) | Fact Sheets (0) | Press Releases (1)
sort by: Date | Relevance
ABPI Lauds MHRA’s 2014-2015 Business Plan [Published FDA News - Apr 18 2014]
Press release: Two men sentenced for fake condo... [Published MHRA - Apr 17 2014]
MHRA business plan new products services income... [Published Big News Network - Apr 16 2014]
UK industryMHRA generics quality forum launches [Published Big News Network - Apr 16 2014]
Pharmacist appointed director of licensing at MHRA [Published Pharmacy.Biz - Apr 16 2014]
MHRA appoints new Director of Licensing [Published Pharma Field - Apr 16 2014]
Press release: MHRA appoints new Director of Li... [Published MHRA - Apr 16 2014]
UK industry/MHRA generics quality forum launches [Published Pharma Times - Apr 16 2014]
BGMA and MHRA create forum to examine generic d... [Published Pharmacy.Biz - Apr 16 2014]
MHRA business plan: new products, services, inc... [Published Pharma Times - Apr 16 2014]
Cheap drugs and the millionaire whistleblower [Published New Internationalist - Apr 16 2014]
MOLECULAR PROFILES EXPANDS TECHNOLOGY WITH GMP ... [Published PharmiWeb - Apr 14 2014]
3M’s Tegaderm CHG IV dressing is first transpar... [Published IVTEAM - Apr 13 2014]
Molecular Profiles Invests in Hot Melt Extrusio... [Published PharmTech.com - Apr 10 2014]
The Conversation UK: Britain's Efforts to Redu... [Published Huffington Post UK - Apr 10 2014]
CT regulation cleared by Parliament with CCI ex... [Published Pharma Times - Apr 08 2014]
MHRA: many healthcare apps likely to qualify as... [Published Matthew Arnold & Baldwin LLP - Apr 08 2014]
Consultation outcome: Certificates of Free Sale... [Published Cabinet Office - Apr 08 2014]
Quality by Design—Bridging the Gap between Conc... [Published PharmTech.com - Apr 08 2014]
MHRA invites applications for Early Access to M... [Published Pharmacy.Biz - Apr 07 2014]
Arno Therapeutics Enrolls First Patient in a Ph... [Published Virtual Strategy Magazine - Apr 07 2014]
Arno Therapeutics : Enrolls First Patient in a ... [Published 4 Traders - Apr 07 2014]
Press Release: Early Access to Medicines Scheme... [Published MHRA - Apr 07 2014]
Early Access to Medicines Scheme (EAMS) [Published MHRA - Apr 07 2014]
3M’s Tegaderm CHG IV dressing is first... [Published IVTEAM - Apr 06 2014]
Pharmacists highlight concerns over law change ... [Published PJ Online - Apr 03 2014]
This week: Petards Fit for Growth, Galasys off ... [Published Proactiveinvestors United Kingdom website - Apr 03 2014]
Kopran receives UK MHRA approval for Khopoli fa... [Published Business Standard India - Apr 03 2014]
Kopran shines on receiving Certificate of Compl... [Published Arihant Capital - Apr 03 2014]
Kopran's Finished Dosage Forms facility gets UK... [Published Business Standard India - Apr 02 2014]
1 2 3 4
In Focus
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
Content Volume
Document Volume
Network
Network

Blogs

sort by: Date | Relevance
This week: Petards Fit for Growth, Galasys off ... [Published Proactiveinvestors United Kingdom website - Apr 03 2014]
BILL debt reduction,CCE award,CHRR trading update,ECK payment contracts,Galasys Intention to float on AIM,Haydale Graphene Industries Intention to float on AIM,PPT Pay in Your Currency,PEG final results,RAME Energy Intention to float on AIM,RENE UK regulatory ...
e-Therapeutics announces recruitment resumes in... [Published PBR - News - Mar 27 2014]
e-Therapeutics has announced that it has received approval from Medicines and Healthcare products Regulatory Agency (MHRA) to recommence recruitment of new patients into its ETS2101 Phase Ia solid tumors trial being conducted at three centers in the ...
Blowing smoke [Published PharmaGossip - Feb 20 2014]
Glaxo Memo Shows Drug Industry Lobbying on E-Cigarettes GlaxoSmithKline Plc (GSK)  is pushing for more stringent regulation of electronic cigarettes, which compete with its  Nicorette  gum and other smoking cessation products, according to e-mails from ...
MHRA issue drug safety update on interferon-beta [Published MS News - Feb 12 2014]
The Medicines and Healthcare products Regulatory Agency (MHRA) is investigating 10 reports in the UK of ‘thrombotic microangiopathy’, a blood disorder associated with interferon-beta which can affect the kidneys. They issued a  drug safety update ...
[Editorial] The beginning of the end of consist... [Published The Lancet Neurology - Jan 20 2014]
The ongoing debate over the safety of switching between oral antiepileptic drugs (AEDs) from different manufacturers has recently been rekindled by new guidelines issued by the UK Medicines and Healthcare products Regulatory Agency ( MHRA). Compiled ...
1

Press Releases

sort by: Date | Relevance
Pharmacyclics, Acacia Research, Alnylam Pharmac... [Published PR Newswire - Oct 31 2013]
1
Contact Us
Sales
Support


Freebase CC-BY Some image thumbnails are sourced from Freebase, licensed under CC-BY

Copyright (C) 2014 Silobreaker Ltd. All rights reserved.
The selection and placement of stories and images on any Silobreaker page are determined automatically by a computer program.
The time or date displayed reflects when an article was added to or updated in Silobreaker.